Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    JZP-110 hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,445Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Axsome Pharma Resolves SUNOSI Patent Dispute With Alkem Labs
    Axsome Pharma Resolves SUNOSI Patent Dispute With Alkem Labs

    17 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/17/3239072/33090/en/Axsome-Therapeutics-Settles-SUNOSI-solriamfetol-Patent-Litigation-with-Alkem-Laboratories-Ltd.html

    GLOBENEWSWIRE
    17 Feb 2026
    Share Share
    Aurobindo’s Generics Solriamfetol Receives Tent. Approval in US
    Aurobindo’s Generics Solriamfetol Receives Tent. Approval in US

    04 Feb 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218725

    FDA
    04 Feb 2026
    Share Share
    Axsome Therapeutics Settles Sunosi Patent Dispute with Hetero Lab
    Axsome Therapeutics Settles Sunosi Patent Dispute with Hetero Lab

    27 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/27/3088458/33090/en/Axsome-Therapeutics-Settles-SUNOSI-solriamfetol-Patent-Litigation-with-Hetero-Labs-Ltd.html

    GLOBENEWSWIRE
    27 May 2025
    Share Share
    Axsome to narrow focus of depression drug trial after limited success
    Axsome to narrow focus of depression drug trial after limited success

    02 Apr 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/axsomes-depression-treatment-fails-meet-main-goal-late-stage-study-2025-04-01/

    REUTERS
    02 Apr 2025
    Share Share
    Axsome's Sunosi scores in phase 3 ADHD trial
    Axsome's Sunosi scores in phase 3 ADHD trial

    26 Mar 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/axsome-touts-success-phase-3-trial-sunosi-adhd

    FIERCE PHARMA
    26 Mar 2025
    Share Share
    Axsome Therapeutics Settles Sunosi Patent Litigation with Hikma
    Axsome Therapeutics Settles Sunosi Patent Litigation with Hikma

    05 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/05/3037271/33090/en/Axsome-Therapeutics-Settles-Sunosi-solriamfetol-Patent-Litigation-with-Hikma-Pharmaceuticals-USA.html

    GLOBENEWSWIRE
    05 Mar 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.